Gain Therapeutics, Inc. (GANX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$16.6M
Cash & Equivalents
$4.7M
Quarterly Burn Rate
11 mo
Est. Cash Runway
$77M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06732180 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease | PHASE1 | Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-29 | 8-K | Gain Therapeutics, Inc. (GANX) (CIK 0001819411) - FORM 8-K | EDGAR |